Journal of the Anus Rectum and Colon最新文献

{"title":"Multi-Institutional Registry of Large Bowel Cancer in Japan Conducted by the Japanese Society for Cancer of the Colon and Rectum in 2024: Cases Treated in 2016.","authors":"Hirotoshi Kobayashi, Michio Asano, Megumi Ishiguro, Soichiro Ishihara, Masafumi Inomata, Yukihide Kanemitsu, Koji Komori, Hiroshi Matsumoto, Kenichi Sugihara, Yoichi Ajioka","doi":"10.23922/jarc.2025-050","DOIUrl":"https://doi.org/10.23922/jarc.2025-050","url":null,"abstract":"<p><strong>Objectives: </strong>Colorectal cancer is the most common malignant disease in Japan. This study aimed to publish data on colorectal cancer cases registered in 2024, focusing on patients who received initial treatment in 2016.</p><p><strong>Methods: </strong>Participating facilities of the Japanese Society for Cancer of the Colon and Rectum (JSCCR) registered cases treated in 2016 according to the 8th edition of the Japanese Classification of Colorectal Carcinoma. Data submitted to the National Registration Committee in 2024 were analyzed.</p><p><strong>Results: </strong>A total of 12,825 cases were analyzed. Of these, 1,091 patients underwent endoscopic treatment, 756 underwent additional surgical resection after endoscopic treatment, and 10,806 underwent surgical treatment. Notably, among patients treated endoscopically, the proportion of endoscopic submucosal dissection (ESD) cases increased from 10.1% in 2010 to 25.5% in 2016.</p><p><strong>Conclusions: </strong>This report describes the characteristics, treatment methods, and outcomes of colorectal cancer patients receiving initial treatment in 2016 at JSCCR-affiliated facilities. Notably, the proportion of cases with ESD among all endoscopic procedures increased by more than twofold between 2010 and 2016. These data are expected to be useful for patients to better understand their disease and for healthcare professionals when explaining colorectal cancer and its treatments to patients.</p>","PeriodicalId":56349,"journal":{"name":"Journal of the Anus Rectum and Colon","volume":"10 1","pages":"1-7"},"PeriodicalIF":1.5,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854283/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146108579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Preoperative Cancer-Specific Glasgow Prognostic Score Strongly Predicts Survival in Stage II/III Colorectal Cancer.","authors":"Teppei Kamada, Yasuhiro Takano, Keisuke Goto, Shu Tsukihara, Tadashi Abe, Yasunobu Kobayashi, Yuta Imaizumi, Shunjin Ryu, Yasuhiro Takeda, Masahisa Ohkuma, Makoto Kosuge, Ken Eto","doi":"10.23922/jarc.2025-084","DOIUrl":"10.23922/jarc.2025-084","url":null,"abstract":"<p><strong>Objectives: </strong>The Glasgow Prognostic Score (GPS), derived from serum C-reactive protein (CRP) and albumin (Alb) levels, is a validated prognostic marker in colorectal cancer (CRC). However, it lacks tumor-specific components. Carcinoembryonic antigen (CEA) is indicative of tumor burden and biology. To enhance prognostic stratification, we developed the Cancer-Specific Glasgow Prognostic Score (C-GPS), which integrates GPS with CEA.</p><p><strong>Methods: </strong>We retrospectively analyzed 753 patients with Stage II/III CRC who underwent curative resection between 2008 and 2018. The C-GPS was calculated by assigning one point each for CEA >5.0 ng/mL, Alb <3.5 g/dL, and CRP >1.0 mg/dL. Patients were categorized into Low (0), Mid (1-2), and High (3) C-GPS groups. Survival outcomes were evaluated using Kaplan-Meier and Cox regression models, and prognostic discrimination was assessed using the concordance index (C-index).</p><p><strong>Results: </strong>The 5-year disease-free survival (DFS) and overall survival (OS) rates were significantly lower in the High C-GPS group (62.1% and 72.7%, respectively; p<0.01). Multivariate analysis identified High C-GPS as an independent predictor of poor DFS (HR: 1.76, 95% CI: 1.01-3.10, p=0.049) and OS (HR: 1.30, 95% CI: 1.01-1.66, p=0.034). The C-GPS demonstrated superior prognostic discrimination compared to GPS for both DFS (C-index: 0.583 vs. 0.524) and OS (0.633 vs. 0.576).</p><p><strong>Conclusions: </strong>C-GPS is a simple and clinically feasible composite index that provides better prognostic accuracy than GPS by incorporating tumor burden, systemic inflammation, and nutritional status to stratify patients with CRC following curative surgery.</p>","PeriodicalId":56349,"journal":{"name":"Journal of the Anus Rectum and Colon","volume":"10 1","pages":"54-63"},"PeriodicalIF":1.5,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146108582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Japan Society of Coloproctology Practice Guidelines for Fecal Incontinence 2024 (Revised Second Edition).","authors":"Keiji Koda, Toshiki Mimura, Tetsuo Yamana, Mitsuru Ishizuka, Tomoko Takahashi, Shota Takano, Tatsuya Abe, Yuji Nishizawa, Hidetoshi Katsuno, Masami Sato, Kaoru Nishimura, Masahiro Yoshida, Kotaro Maeda","doi":"10.23922/jarc.2025-042","DOIUrl":"10.23922/jarc.2025-042","url":null,"abstract":"&lt;p&gt;&lt;p&gt;In 2024, the second edition of the Japan Society of Coloproctology (JSCP) Practice Guidelines for Fecal Incontinence was published in Japan, followed by the release of this English version. This marks the first major revision in 7 years since the publication of the first edition. The second edition was completed over a span of 3 years, and its overview and key features are summarized below. This guideline begins with a clinical flowchart outlining the general diagnostic and therapeutic approach. A notable update is the inclusion of insertable anal and vaginal continence devices, which are now considered a form of conservative therapy under clinical research frameworks. In Chapter I-B (Epidemiology), the prevalence of anal incontinence was newly reported: among a Japanese population with an average age of 35 years, 15.5% of men and 42.7% of women were affected. In Chapter II (Diagnosis), the utility of a bowel diary for patient assessment is discussed for the first time. The guideline also provides a detailed description of the evaluation method for digital rectal examination. Additionally, a new section was added addressing incontinence-associated dermatitis (IAD), including its risks and methods of assessment. In Chapter III (Diagnostic Testing), the guideline expands upon previously established diagnostic tests by newly including detailed descriptions of ultrasound techniques-specifically, endoanal ultrasound, transperineal ultrasound, and transvaginal ultrasound. Chapter IV (Treatment) outlines conservative treatment strategies, including dietary guidance, bowel habit instruction, and care for fecal incontinence. Pharmacologic therapies are presented with itemized explanations by drug type. Pelvic floor muscle training, biofeedback therapy, and transanal irrigation are classified under \"specialized conservative therapies\" and discussed in detail. For surgical treatment, a new Clinical Question (CQ) addresses postpartum fecal incontinence. It recommends early referral to a specialized center when a sphincter injury is present to be repaired, whereas observation for one year may be appropriate when no injury is identified. Another new CQ discusses the mode of delivery in subsequent pregnancies following obstetric anal sphincter injuries (OASIS), emphasizing the need to evaluate fecal incontinence severity, anal sphincter function, and its integrity before making clinical decisions. Stoma creation is described in detail as one of the surgical treatment options, including its implications for improved postoperative quality of life. For the first time, regenerative therapy for the anal sphincter is introduced as a novel surgical option, reporting promising long-term outcomes from trials involving the transplantation of autologous cultured myoblasts into the external anal sphincter. Finally, Chapter V addresses special clinical scenarios in detail, including fecal incontinence associated with neurological and spinal disorders, dementia, frailt","PeriodicalId":56349,"journal":{"name":"Journal of the Anus Rectum and Colon","volume":"10 1","pages":"64-134"},"PeriodicalIF":1.5,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854284/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146108634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intracorporeal Anastomosis for Robotic-assisted Right Hemicolectomy Using an Umbilical Assistant Port.","authors":"Yusuke Kitagawa, Hisanori Miki, Takumi Yamamoto, Hiroki Uehara, Shoichiro I, Norikazu Yamada, Yuto Igarashi, Toshinori Kobayashi, Yoshihiro Mori, Jun Watanabe, Yosuke Fukunaga","doi":"10.23922/jarc.2025-044","DOIUrl":"10.23922/jarc.2025-044","url":null,"abstract":"<p><p>There is ongoing debate on the respective merits of extracorporeal and intracorporeal anastomoses in patients undergoing minimally invasive surgery for right-sided colon cancer. Herein, we report the benefits of intracorporeal anastomosis for right-sided colon cancer using an umbilical assistant port. The final decision to perform an intracorporeal or extracorporeal anastomosis was made intraoperatively. Robotic ports were established; the Da Vinci Xi robotic system was used with the specified instrument configuration. The benefits of intracorporeal anastomosis for right-sided colon cancer using an umbilical assistant port include reduced stress for the surgical team and improved adaptability. Although techniques differ, standardizing practices tailored to each team's strengths is vital for advancing robotic-assisted surgery. This method minimizes lower abdominal incisions, thereby reducing the risk of wound infection and incidence of postoperative hernia. Comprehensive evidence of robotic-assisted colon surgery remains limited, underscoring the need for ongoing evaluation and refinement of techniques.</p>","PeriodicalId":56349,"journal":{"name":"Journal of the Anus Rectum and Colon","volume":"10 1","pages":"184-188"},"PeriodicalIF":1.5,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854285/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146108607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robot Assisted Low Anterior Resection for Obese Rectal Cancer Patients: A Single-center Analysis of Short-term Outcomes.","authors":"Fuminori Teraishi, Yusuke Yoshida, Ryohei Shoji, Nobuhiko Kanaya, Yuki Matsumi, Kunitoshi Shigeyasu, Yoshitaka Kondo, Shunsuke Kagawa, Toshiyoshi Fujiwara","doi":"10.23922/jarc.2025-015","DOIUrl":"10.23922/jarc.2025-015","url":null,"abstract":"<p><strong>Objectives: </strong>This study evaluates the short-term safety and technical feasibility of robot-assisted low anterior resection (RALAR) for rectal cancer in obese patients (BMI ≥ 25 kg/m²) compared to non-obese patients.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted on patients undergoing RALAR for rectal cancer at Okayama University Hospital (September 2020-January 2025). Patients were divided into obese (BMI ≥ 25 kg/m²) and non-obese (BMI < 25 kg/m²) groups. Patient characteristics, surgical data, and postoperative outcomes were analyzed. Statistical analysis was performed using appropriate tests (Student's t-test, Mann-Whitney U test) with a significance level of p < 0.05.</p><p><strong>Results: </strong>The study included 27 obese and 49 non-obese patients. The obese group had a significantly higher median BMI (28.1 vs. 21.6 kg/m², p < 0.01) and a higher proportion of patients with ASA classification ≥ 2 (81.5% vs. 57.1%, p = 0.03). There were no significant differences in operative time, console time, estimated blood loss, or conversion rate to open surgery. Postoperative complication rates were similar between groups (p=0.13). The incidence of severe complications (Clavien-Dindo grade III or higher) and anastomotic leakage were also not significantly different. Postoperative length of stay was comparable.</p><p><strong>Conclusions: </strong>RALAR for obese rectal cancer patients is feasible, despite trends toward increased technical difficulty (more staple firings, longer operative times, higher blood loss, complications). No conversions occurred, and hospital stays were comparable.</p>","PeriodicalId":56349,"journal":{"name":"Journal of the Anus Rectum and Colon","volume":"10 1","pages":"34-42"},"PeriodicalIF":1.5,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854286/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146108653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathological Response of Locally Recurrent Rectal Cancer to Neoadjuvant Chemoradiotherapy.","authors":"Yuichiro Yokoyama, Kosuke Ozaki, Hiroaki Nozawa, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Kensuke Kaneko, Hiroyuki Matsuzaki, Shinya Abe, Yuzo Nagai, Takahide Shinagawa, Soichiro Ishihara","doi":"10.23922/jarc.2025-065","DOIUrl":"10.23922/jarc.2025-065","url":null,"abstract":"<p><strong>Objectives: </strong>The primary objective was to elucidate the apoptotic response of locally recurrent rectal cancer (LRRC) to neoadjuvant chemoradiotherapy (CRT) using M30 CytoDeath immunostaining. Secondary objectives were to examine its association with tumor regression grade (TRG), tumor size reduction, and long-term outcomes.</p><p><strong>Methods: </strong>This retrospective study included nine patients who underwent CRT followed by radical surgery for LRRC between 2012 and 2020. TRG was evaluated according to the Japanese Classification of Colorectal Carcinoma. Apoptosis was assessed with M30 CytoDeath immunostaining, in which the proportion of stained cells was classified as score 0 (0-33%), score 1 (34-66%), score 2 (67-99%), and score 3 (100%). Tumor size reduction, R0 resection rate, and survival outcomes were also analyzed.</p><p><strong>Results: </strong>No patient achieved pathological complete response; most were TRG 1. By M30 CytoDeath staining, no case had a score ≥2, while score 0 was dominant. A few patients showed score 1, including those treated with oxaliplatin or irinotecan in addition to tegafur and uracil/leucovorin. Tumor size reduction was achieved in most patients, with an R0 resection rate of 77.8%. Among R0 cases, 5-year local re-recurrence-free and 3-year disease-free survival rates were 42.9% and 14.3%, respectively.</p><p><strong>Conclusions: </strong>Direct assessment of apoptosis demonstrated that LRRC is resistant to CRT-induced apoptosis. This resistance likely contributes to high local and distant recurrence after surgery, underscoring the need to develop more effective perioperative strategies for LRRC.</p>","PeriodicalId":56349,"journal":{"name":"Journal of the Anus Rectum and Colon","volume":"10 1","pages":"19-25"},"PeriodicalIF":1.5,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854288/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146108604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concomitant <i>RAS</i> and <i>BRAF</i> V600E Mutations in Unresectable Metastatic CRC: A Case of Long-term Survival.","authors":"Kazuo Kitagawa, Naoto Takahashi, Mizuki Fukuda, Yoshito Hannya, Sayumi Kurita, Yuya Shimoyama, Tomotaka Kumamoto, Naoki Toya, Ken Eto","doi":"10.23922/jarc.2025-008","DOIUrl":"10.23922/jarc.2025-008","url":null,"abstract":"<p><p>Detection of rat sarcoma virus (<i>RAS</i>) and B rapidly accelerated fibrosarcoma (<i>BRAF</i>) mutations is critical for selecting an appropriate treatment for metastatic colorectal cancer (mCRC). Although <i>RAS</i> and <i>BRAF</i> V600E mutations are traditionally mutually exclusive, they occasionally co-occur. The concurrent occurrence of <i>RAS</i> and <i>BRAF</i> V600E mutations is rare, with an incidence of < 0.001-0.05% in CRC. Treatment outcomes for cases involving concurrent occurrence of these mutations remain unclear, with reported cases exhibiting a poor prognosis of approximately 1 year. Moreover, reports on the long-term survival of patients with unresectable mCRC with concurrent mutations are lacking. The present study reports a rare case of long-term survival of over 39 months in a patient with mCRC harboring both <i>RAS</i> and <i>BRAF</i> V600E mutations, where chemotherapy alone was effective without surgical resection of the primary or metastatic lesions.</p>","PeriodicalId":56349,"journal":{"name":"Journal of the Anus Rectum and Colon","volume":"10 1","pages":"169-177"},"PeriodicalIF":1.5,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146108562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robotic Right Hemicolectomy for Cecal Cancer with a Rare Ileocolic Artery-Middle Colic Artery Common Trunk: A Case Report.","authors":"Junko Mukohyama, Kenji Ino, Satoko Monma, Naoki Sakuyama, Hiroyuki Akai, Dai Shida","doi":"10.23922/jarc.2025-057","DOIUrl":"10.23922/jarc.2025-057","url":null,"abstract":"<p><p>While venous anomalies of the right colon are relatively common, arterial variations are rare. We report a case of cecal cancer with a unique vascular anomaly. A 65-year-old man presented with fatigue and melena. Colonoscopy revealed a cecal tumor, and biopsy confirmed moderately differentiated adenocarcinoma. Contrast-enhanced CT and three-dimensional CT angiography (3D-CTA) demonstrated a rare arterial anomaly in which the ileocolic artery (ICA) and middle colic artery (MCA) arose from a common trunk branching ventral to the superior mesenteric vein (SMV). The ICA coursed parallel to the ileocolic vein (ICV), while the MCA ran cranially along the ventral aspect of the SMV. Robot-assisted right hemicolectomy with D3 lymphadenectomy was performed. The ICA was divided distal to its bifurcation from the common trunk. The MCA was meticulously isolated during lymphadenectomy and traced cranially to its bifurcation, where the right branch was divided while preserving the left branch. Final pathology revealed T3 N1b (2/51) M0, Stage IIIB, with negative margins. This case highlights the value of preoperative 3D-CTA in detecting rare vascular anomalies and tailoring surgical strategies, and underscores how robot-assisted surgery, combined with precise preoperative imaging, facilitates optimal management in anatomically complex colorectal cases.</p>","PeriodicalId":56349,"journal":{"name":"Journal of the Anus Rectum and Colon","volume":"10 1","pages":"178-183"},"PeriodicalIF":1.5,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146108647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Propensity Score-matched Analysis of the Impact of Direct-acting Oral Anticoagulants on Fecal Immunochemical Test Performance.","authors":"Yasuhiko Hamada, Akina Shigefuku, Hiroto Suzuki, Aiji Hattori, Yuhei Umeda, Yohei Ikenoyama, Hiroki Yukimoto, Chihiro Iwashita, Yasuko Fujiwara, Misaki Nakamura, Noriyuki Horiki, Hayato Nakagawa","doi":"10.23922/jarc.2025-026","DOIUrl":"10.23922/jarc.2025-026","url":null,"abstract":"<p><strong>Objectives: </strong>The fecal immunochemical test (FIT) is widely used for colorectal cancer (CRC) screening, owing to its high diagnostic accuracy. Antithrombotic medications, particularly direct-acting oral anticoagulants (DOACs), can influence FIT performance; however, the evidence concerning this phenomenon remains inconsistent in the literature. This study evaluated the impact of DOACs on the positive predictive value (PPV) of FIT for diagnosing advanced neoplasia (AN).</p><p><strong>Methods: </strong>This retrospective study, conducted at Mie University Hospital, analyzed 818 patients who underwent colonoscopy procedures following positive FIT results between 2015 and 2024. A propensity score-matched analysis was used to compare PPVs for AN, advanced adenoma, invasive cancer, and all adenomas in the patients who did and did not use DOAC. A logistic regression model was used to conduct a sensitivity analysis evaluating the associations between DOAC use and FIT performance.</p><p><strong>Results: </strong>AN was diagnosed in 4.0% of the DOAC users and 16.8% of the non-users. Our propensity score-matched analysis confirmed that the PPV for AN in the DOAC-user group was significantly lower than that in the non-user group (odds ratio 0.20, 95% confidence interval 0.05-0.92, <i>p</i> = 0.038). Sensitivity analyses supported these findings, indicating reduced FIT performance among the DOAC users (odds ratio 0.25, 95% confidence interval 0.08-0.83, <i>p</i> = 0.024).</p><p><strong>Conclusions: </strong>DOAC use significantly reduced the PPV of FIT for diagnosing AN. This finding suggests that current guidelines should consider alternative strategies, such as adjunctive diagnostic tools, to improve accuracy and reduce unnecessary colonoscopies in patients using DOACs.</p>","PeriodicalId":56349,"journal":{"name":"Journal of the Anus Rectum and Colon","volume":"10 1","pages":"26-33"},"PeriodicalIF":1.5,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146108682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2024 for the Clinical Practice of Inflammatory Bowel Disease-Associated Intestinal Neoplasia (English Version).","authors":"Soichiro Ishihara, Shinji Tanaka, Toshio Uraoka, Yutaka Saito, Hiroyuki Takamaru, Hiroshi Nakase, Makoto Naganuma, Tadakazu Hisamatsu, Toshimitsu Fujii, Minoru Matsuura, Takayuki Matsumoto, Kenji Watanabe, Hiroki Ikeuchi, Motoi Uchino, Yoshiki Okita, Koji Okabayashi, Kazutaka Koganei, Akira Sugita, Kenichi Takahashi, Keisuke Hata, Daijiro Higashi, Kitaro Futami, Keiji Matsuda, Tsunekazu Mizushima, Yusuke Watadani, Hiroshi Kawachi, Masayuki Shimoda, Tamotsu Sugai, Masahiro Yoshida, Naohiko Yamaguchi, Michio Itabashi, Hiroyuki Anzai, Junko Kishikawa, Koichi Komatsu, Takahide Shinagawa, Tatsuya Tsushima, Tatsuki Noguchi, Satoshi Okada, Kenichi Sugihara, Yoichi Ajioka","doi":"10.23922/jarc.2025-071","DOIUrl":"10.23922/jarc.2025-071","url":null,"abstract":"<p><p>The number of patients with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), continues to increase in many countries and regions. With recent rapid advances in medical therapies targeting intestinal inflammation, the number of patients with long-term disease duration is also increasing. It is well-recognized that longstanding IBD carries an increased risk of developing gastrointestinal (GI) neoplasia, particularly colorectal cancer. However, compared to sporadic GI tumors, IBD-associated GI tumors are relatively rare, and even among specialists in GI diseases, opportunities to encounter such cases remain limited. In light of this situation, the Japanese Society for Cancer of the Colon and Rectum (JSCCR), in collaboration with the Japanese Inflammatory Bowel Disease Research Group (funded by the Japan Sciences Research Grant for Research on Intractable Diseases affiliated with the Ministry of Health, Labour, and Welfare) launched the Guideline Development Committee for IBD-associated Gastrointestinal Tumors in 2021, with the aim of establishing clinical practice guidelines to support the diagnosis and management of these tumors. The committee-comprising experts in gastroenterology, surgery, pathology, guideline development, and literature review-conducted extensive discussions and successfully published the first Japanese edition of the guidelines in July 2024. We believe that the current edition provides the best possible guidance based on presently available knowledge. Furthermore, the guideline development process highlighted several key issues to be addressed in future research and clinical practice. We are pleased to present here the English version of the JSCCR Guidelines 2024 for the Clinical Practice of IBD-associated Intestinal Neoplasia.</p>","PeriodicalId":56349,"journal":{"name":"Journal of the Anus Rectum and Colon","volume":"10 1","pages":"135-168"},"PeriodicalIF":1.5,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146108545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}